Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan
- PMID: 18803984
- DOI: 10.1016/j.clinthera.2008.08.007
Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan
Abstract
Objectives: This paper reviews available information on insulin regimens that may enable patients with type 1 diabetes mellitus to fast during the month of Ramadan with minimal complications. It also provides guidance for health care professionals in managing patients who wish to observe the fast.
Methods: Relevant English-language articles were identified through searches of the MEDLINE, EMBASE, and Index Medicus Eastern Mediterranean Region databases (all, 1980-2008) conducted in February 2008 using the terms Ramadan, fasting, type 1 diabetes mellitus, hypoglycemia, and hypotension. Only original research and review articles related to adult patients with type 1 diabetes were considered for review, excluding pregnant women and patients with poorly controlled disease.
Results: The literature review identified 5 clinical trials relevant to type 1 diabetes and fasting. Two main meals are eaten during Ramadan, one before dawn (Suhur) and the other at sunset (Iftar). Suggested adjustments to the insulin regimen during fasting include using 70% of the pre-Ramadan dose, divided as follows: 60% as insulin glargine given in the evening and 40% as an ultra-short-acting insulin (insulin aspart or lispro) given in 2 doses, 1 at Suhur and 1 at Iftar. Alternatively, 85% of the pre-Ramadan dose may be divided as 70% Ultralente and 30% regular insulin, both given in 2 doses, 1 at Suhur and 1 at Iftar. Another option is to give 100% of the pre-Ramadan morning dose of 70/330 premixed insulin at Iftar and 50% of the usual evening dose at Suhur. Patients who observe the fast should be advised to monitor their blood glucose regularly,avoid skipping meals or overeating,and maintain contact with their physician throughout the fast. The fast should be broken immediately if blood glucose drops below 60 mg/dL (3.3 mmol/L). Breaking the fast should be considered when blood glucose drops below 80 mg/dL (4.4 mmol/L), and the fast should be interrupted if blood glucose rises above 300 mg/dL (16.7 mmol/L) to avoid diabetic ketoacidosis. Fasting is contraindicated in patients with poorly controlled type 1 diabetes,including those with a history of severe hypoglycemia and/ or diabetic ketoacidosis at least 3 months before Ramadan; those with comorbid conditions (eg, unstable angina, uncontrolled hypertension, advanced macrovascular complications, infections, renal insufficiency);; those who are noncompliant with diet and medication; those who engage in intense physical activity; pregnant women; and the elderly.
Conclusion: Patients with type 1 diabetes who wish to fast during Ramadan should follow specific recommendations and be closely monitored by their physician.
Similar articles
-
Treatment of type 1 diabetes with insulin lispro during Ramadan.Diabetes Metab. 2001 Sep;27(4 Pt 1):482-6. Diabetes Metab. 2001. PMID: 11547222 Clinical Trial.
-
Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.Acta Diabetol. 2009 Mar;46(1):63-5. doi: 10.1007/s00592-008-0062-7. Epub 2008 Sep 30. Acta Diabetol. 2009. PMID: 18825302
-
Safety and tolerability of once or twice daily neutral protamine hagedorn insulin in fasting pregnant women with diabetes during Ramadan.J Obstet Gynaecol Res. 2011 Feb;37(2):132-7. doi: 10.1111/j.1447-0756.2010.01330.x. Epub 2010 Dec 16. J Obstet Gynaecol Res. 2011. PMID: 21159037
-
Diabetes and Ramadan: review of the literature.Diabetes Res Clin Pract. 2006 Aug;73(2):117-25. doi: 10.1016/j.diabres.2005.10.028. Epub 2006 May 2. Diabetes Res Clin Pract. 2006. PMID: 16647781 Review.
-
Dosing of insulin glargine in the treatment of type 2 diabetes.Clin Ther. 2007 Jun;29(6):987-99. doi: 10.1016/j.clinthera.2007.06.018. Clin Ther. 2007. PMID: 17692716 Review.
Cited by
-
A Nutritional Approach to Optimizing Pump Therapy in Type 1 Diabetes Mellitus.Nutrients. 2023 Nov 23;15(23):4897. doi: 10.3390/nu15234897. Nutrients. 2023. PMID: 38068755 Free PMC article. Review.
-
Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin.Int J Clin Pract. 2010 Jan;64(2):149-59. doi: 10.1111/j.1742-1241.2009.02235.x. Int J Clin Pract. 2010. PMID: 20089006 Free PMC article.
-
Recommendations for fasting in Ramadan for patients on peritoneal dialysis.Perit Dial Int. 2013 Jan-Feb;33(1):86-91. doi: 10.3747/pdi.2010.00095. Perit Dial Int. 2013. PMID: 23349195 Free PMC article.
-
Empowerment-Based Diabetes Self-Management Education to Maintain Glycemic Targets During Ramadan Fasting in People With Diabetes Who Are on Conventional Insulin: A Feasibility Study.Diabetes Spectr. 2017 Feb;30(1):36-42. doi: 10.2337/ds15-0058. Diabetes Spectr. 2017. PMID: 28270713 Free PMC article.
-
Impact of Ramadan Diurnal Intermittent Fasting on Hypoglycemic Events in Patients With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials and Observational Studies.Front Endocrinol (Lausanne). 2021 Mar 8;12:624423. doi: 10.3389/fendo.2021.624423. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33763029 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical